Biotech Values

[vinmantoo]

As far as I can tell, the MIRASOL trial included only high FR-alpha expressers. IMGN’s previous phase-3 FORWARD-1 trial that failed in 2019 included high and moderate FR-alpha expressers (https://www.businesswire.com/news/home/20190301005092/en/ImmunoGen-Announces-Top-Line-Results-Phase-3-Study ), and showed promising results in the high-expresser subgroup.

Dew, sorry for the brain fart. I did know MIRASOL was only high receptor expression. Thanks for providing the correct info. I do recall the failure of the FORWARD trial of high and medium expression but IMGN did an the analysis which showed high expressors did well. That is what MIRASOL and SOROYA both only had high expression patients.

IMGN has 3 other Elahere trials too. One as monotherapy (PICCOLO) in high expressors with platinum sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers. One combination study for high expressors is GLORIOSO, has Elahere with Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer. The other IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive. This trial doesn't say high expressors only positive.

https://www.clinicaltrials.gov/ct2/show/NCT05456685